ACCRETAMAB

Serial Number 77178675
Registration 3653037
800

Registration Progress

Application Filed
May 11, 2007
Under Examination
Approved for Publication
Apr 8, 2009
Published for Opposition
Apr 28, 2009
Registered
Jul 14, 2009

Trademark Image

ACCRETAMAB

Basic Information

Serial Number
77178675
Registration Number
3653037
Filing Date
May 11, 2007
Registration Date
July 14, 2009
Published for Opposition
April 28, 2009
Renewal Date
July 14, 2019
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
800
Status Date
Apr 10, 2019
Registration
Registered
Classes
005 040 042

Rights Holder

KYOWA KIRIN CO., LTD.

03
Address
1-9-2, OTEMACHI, CHIYODA-KU
TOKYO
JP

Ownership History

KYOWA HAKKO KOGYO CO., LTD.

Original Applicant
03
Chiyoda-ku Tokyo JP

KYOWA HAKKO KIRIN CO., LTD.

New Owner Before Publication #1
03
CHIYODA-KU, TOKYO JP

KYOWA HAKKO KIRIN CO., LTD.

Owner at Publication
03
CHIYODA-KU, TOKYO JP

KYOWA HAKKO KIRIN CO., LTD.

Original Registrant
03
CHIYODA-KU, TOKYO JP

KYOWA KIRIN CO., LTD.

New Owner After Registration #1
03
TOKYO JP

Legal Representation

Attorney
Kaushal R. Odedra

USPTO Deadlines

Next Deadline
1341 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2009-07-14)
Due Date
July 14, 2029
Grace Period Ends
January 14, 2030

Application History

40 events
Date Code Type Description Documents
Sep 4, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Apr 10, 2019 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED Loading...
Apr 10, 2019 RNL1 Q REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) Loading...
Apr 10, 2019 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED Loading...
Apr 8, 2019 E89R I TEAS SECTION 8 & 9 RECEIVED Loading...
Jul 14, 2018 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED Loading...
Aug 5, 2015 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Aug 5, 2015 8.PR O REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED Loading...
Aug 5, 2015 NAS8 E NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED Loading...
Jul 1, 2015 ES8R I TEAS SECTION 8 RECEIVED Loading...
Jul 14, 2009 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 28, 2009 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 8, 2009 NPUB O NOTICE OF PUBLICATION Loading...
Mar 23, 2009 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 23, 2009 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Feb 24, 2009 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 24, 2009 ACEC I AMENDMENT FROM APPLICANT ENTERED Loading...
Feb 23, 2009 MAIL I PAPER RECEIVED Loading...
Feb 10, 2009 CNSI S INQUIRY AS TO SUSPENSION MAILED Loading...
Feb 9, 2009 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 9, 2009 ACEC I AMENDMENT FROM APPLICANT ENTERED Loading...
Feb 9, 2009 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Feb 6, 2009 MAIL I PAPER RECEIVED Loading...
Jan 12, 2009 CNSI S INQUIRY AS TO SUSPENSION MAILED Loading...
Jan 11, 2009 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Dec 11, 2008 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Nov 19, 2008 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Jun 11, 2008 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jun 11, 2008 CNSL S LETTER OF SUSPENSION MAILED Loading...
Jun 10, 2008 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 10, 2008 ACEC I AMENDMENT FROM APPLICANT ENTERED Loading...
Jun 9, 2008 MAIL I PAPER RECEIVED Loading...
Mar 26, 2008 CNSI S INQUIRY AS TO SUSPENSION MAILED Loading...
Mar 25, 2008 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Feb 24, 2008 ALIE A ASSIGNED TO LIE Loading...
Feb 24, 2008 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Aug 24, 2007 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 24, 2007 CNSL R SUSPENSION LETTER WRITTEN Loading...
Aug 24, 2007 CNSL F LETTER OF SUSPENSION MAILED Loading...
May 16, 2007 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
[Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases]
First Use Anywhere: 0
First Use in Commerce: 0
Class 040
Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005 040 042